Synthetic Nicotine still is a rather new product that has to “prove itself“ first. CNT’s tobacco-derived nicotine, on the other hand, has a proven safety track record in the pharmaceutical arena that spans well over 30 years. “It does not contain any nitrosamines, pesticides, or tobacco-related impurities, for example myosmine or nornicotine, at detectable levels, and it is extensively tested for its properties,” Dr. Ellerichmann pointed out. Secondly, the cost factor of Synthetic Nicotine comes into play as well. Synthetic Nicotine‘s elaborate production and purifying process currently makes it more expensive than its tobacco-extracted cousin – and that certainly is an important aspect for end-product manufacturers to consider.

And don’t count out the consumer, either. “Many e-liquid customers prefer tobacco-derived nicotine because [to them] ‘Synthetic Nicotine’ sounds chemical and artificial, and having a ‘drug character’,” said Siemann. “Most vapers are ex-smokers and don’t want to reference their habit with ‘drug use’.” As such, he said CNT was presently “only seeing a minor [vaping] market shift towards Synthetic Nicotine,” as overall “the market for Synthetic Nicotine is still not more than 1-2% of global demand.” But he nevertheless expected rising interest once the regulatory situation becomes settled as, “FDA regulations are going to be the main driver.”

But, Siemann nevertheless asserted that CNT saw “great future potential“ for Synthetic Nicotine. That was why the company poured “significant amounts into r&d and production resources into [this] product segment“ in the first place. Yet, he also warned that there currently was a certain hype enveloping the industry that might cause the false impression that Synthetic Nicotine was on the best way of replacing tobacco-derived nicotine altogether. “But CNT doesn’t see this happening at all and we‘d rather believe that there is a growing nicotine products market where synthetic is going to play an increasing role.“

That Synthetic Nicotine – at least at this point – still has a long way to go before catching up to its “natural“ counterpart is also illustrated by the fact that about 95% of all orders presently handled by CNT are coming in from the US. Another 5% trickle in from Asia, primarily South Korea, while so far there has been no demand (as in “zero“) from Europe. Yet, CNT’s S-nicotine products (see product table) are uncompromisingly manufactured under the company’s pharmaceutical-quality system (cGMP) and available as nicotine bitartrate dihydrate (a nicotine salt), nicotine solutions, nicotine polacrilex resin, and nicotine granulate. As the current US trend is rather sooner than later going to fan out more forcefully into other markets, CNT already finds itself in an excellent position to respond immediately.

We specialize in manufacturing chemical Synthetic Nicotine ( CAS No.: 54-11-5 ) in China. we have the highest technology and stable quality control , our factory has sophisticated technology production route to produce the above products ,welcome to inquiry it .Please contact us by e-mail nicotine@haihengpharma.com for quotation requests. Please provide quantity, purity, and any other specific requirements.

Synthetic NicotineSynthetic Nicotine is used for Quitting Smoking
Synthetic Nicotine still is a rather new product that has to “prove itself“ first. CNT’s tobacco-derived nicotine, on the other hand, has a proven safety track record in the pharmaceutical arena that spans well over 30 years. “It does not contain any nitrosamines, pesticides, or tobacco-related impurities, for example...